THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
RESTRICTED & HIGH-RISK MEDICINE MONOGRAPH CODE: [R-10] ID: TIP-MED-000529

Eszopiclone

Active Ingredient / Scientific Identity: Eszopiclone • Class: Dex-Enantiomer Cyclopyrrolone Non-Benzodiazepine Hypnotic

⚖️ Compare Profile
Generic / Entity NameEszopiclone ([R-10])
Verified Indian Brands / RefFulnite (Sun Pharmaceutical Industries), Zopanda (Lupin Ltd), Eszop (Torrent Pharmaceuticals)
Pharmacological ClassDex-Enantiomer Cyclopyrrolone Non-Benzodiazepine Hypnotic
Available Dosage FormsFilm-Coated Tablet: 1 mg, 2 mg, 3 mg
Regulatory ClassificationSchedule H1 (Drugs Rules, 1945)
Key Warning & Review DateNext-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), comple
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 (Drugs Rules, 1945)🚨 Clinically High-Alert: Independent Dose & Route Verification Required👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Eszopiclone (TIP-MED-000529, Reference Code [R-10]) is classified under CNS Hypnotics & Sedatives as a Dex-Enantiomer Cyclopyrrolone Non-Benzodiazepine Hypnotic. Within the Indian regulatory and compendial framework, it is governed under Schedule H1 (Drugs Rules, 1945).

Verified Indian Market Examples / Compendial Status:
Fulnite (Sun Pharmaceutical Industries), Zopanda (Lupin Ltd), Eszop (Torrent Pharmaceuticals)
Representative Indian Market Examples (Educational & Regulatory Identification Only — CDSCO / NFI / Hospital Formulary): Fulnite (Sun Pharmaceutical Industries), Zopanda (Lupin Ltd), Eszop (Torrent Pharmaceuticals) — Film-Coated Tablet: 1 mg, 2 mg, 3 mg.
Dosage Forms & Available Strengths:
Film-Coated Tablet: 1 mg, 2 mg, 3 mg
Routes: Oral (at bedtime)

Statutory Restriction, High-Alert & Dispensing Safeguards

Indian Regulatory & Statutory Control Basis: Schedule H1 (Drugs Rules, 1945)

High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Next-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), complex parasomnias, and additive CNS depression with alcohol.

Mandatory Dispensing Register & Institutional Custody Protocol: Administer immediately before retiring; avoid administration after a high-fat heavy meal (delays Tmax by ~1 hour).

3. Mechanism of Action & Pharmacodynamics

Active S-enantiomer of zopiclone with selective affinity for alpha-1 and alpha-3 containing GABA-A receptors.

4. Therapeutic Indications & Evidence-Supported Uses

  • Sleep-onset and sleep-maintenance insomnia (short-term therapy)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Eszopiclone must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Film-Coated Tablet: 1 mg, 2 mg, 3 mg).

Administration & Meal Timing: Routes: Oral (at bedtime). Administer immediately before retiring; avoid administration after a high-fat heavy meal (delays Tmax by ~1 hour).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Exhibits dex-enantiomer cyclopyrrolone non-benzodiazepine hypnotic pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Metabolism & Biotransformation:
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Elimination & Renal Adjustment:
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Hepatic Impairment Considerations:
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Known severe hypersensitivity to Eszopiclone or formulation excipients
  • Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
  • Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions

Key Clinical Precautions: Next-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), complex parasomnias, and additive CNS depression with alcohol.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Next-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), complex parasomnias, and additive CNS depression with alcohol.
  • Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
Serious / Dose-Limiting Adverse Effects:
  • Next-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), complex parasomnias, and additive CNS depression with alcohol.
  • High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Next-morning psychomotor impairment (especially at 3 mg dose or in elderly patients >65 years where max dose is 2 mg), complex parasomnias, and additive CNS depression with alcohol.
  • Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Administer immediately before retiring; avoid administration after a high-fat heavy meal (delays Tmax by ~1 hour).

Pharmacist Patient Counselling Points:

  • Administer immediately before retiring; avoid administration after a high-fat heavy meal (delays Tmax by ~1 hour).
  • Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.

Storage, Stability & Dispensing Safeguards: Administer immediately before retiring; avoid administration after a high-fat heavy meal (delays Tmax by ~1 hour).

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).

Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.